Literature DB >> 11059750

Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism.

C Sweeney1, G Y McClure, M Y Fares, A Stone, B F Coles, P A Thompson, S Korourian, L F Hutchins, F F Kadlubar, C B Ambrosone.   

Abstract

A glutathione S-transferase (GST) P1 polymorphism results in an amino acid substitution, Ile105Val; the Val-containing enzyme has reduced activity toward alkylating agents. Cancer patients with the variant enzyme may differ in removal of treatment agents and in outcomes of therapy. We evaluated survival according to GSTP1 genotype among women (n = 240) treated for breast cancer. Women with the low-activity Val/Val genotype had better survival. Compared with Ile/Ile, hazard ratios for overall survival were 0.8 (95% confidence interval, 0.5-1.3) for Ile/Val and 0.3 (95% confidence interval, 0.1-1.0) for Val/Val (P for trend = 0.04). Inherited metabolic variability may influence treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059750

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.

Authors:  H Irene Su; Mary D Sammel; Luke Velders; Michelle Horn; Corrie Stankiewicz; Jennifer Matro; Clarisa R Gracia; Jamie Green; Angela DeMichele
Journal:  Fertil Steril       Date:  2009-04-18       Impact factor: 7.329

2.  Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.

Authors:  Patrick Thompson; Heather E Wheeler; Shannon M Delaney; Rachel Lorier; Ulrich Broeckel; Meenakshi Devidas; Gregory H Reaman; Kathleen Scorsone; Lillian Sung; M Eileen Dolan; Stacey L Berg
Journal:  Cancer Chemother Pharmacol       Date:  2014-08-14       Impact factor: 3.333

3.  Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

Authors:  J M Allan; C P Wild; S Rollinson; E V Willett; A V Moorman; G J Dovey; P L Roddam; E Roman; R A Cartwright; G J Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 4.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.

Authors:  Shilong Zhong; Min Huang; Xiuyan Yang; Liuqin Liang; Yixi Wang; Marjorie Romkes; Wei Duan; Eli Chan; Shu-Feng Zhou
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

Review 6.  Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-06-09

Review 7.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

8.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 9.  Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.

Authors:  Navin Pinto; Susan M Ludeman; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

10.  Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.

Authors:  Priya P Gor; H Irene Su; Robert J Gray; Phyllis A Gimotty; Michelle Horn; Richard Aplenc; William P Vaughan; Martin S Tallman; Timothy R Rebbeck; Angela DeMichele
Journal:  Breast Cancer Res       Date:  2010-05-10       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.